Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent or Metastatic”

2,706 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 2,706 results

Testing effectiveness (Phase 2)Study completedNCT03625323
What this trial is testing

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

Who this might be right for
NSCLCHNSCC
Immutep S.A.S. 187
Large-scale testing (Phase 3)Active Not RecruitingNCT04305496
What this trial is testing

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 818
Testing effectiveness (Phase 2)Active Not RecruitingNCT04190446
What this trial is testing

Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer

Who this might be right for
Metastatic Prostate AdenocarcinomaOligometastatic Prostate CarcinomaProstate Adenocarcinoma+2 more
Mayo Clinic 84
Large-scale testing (Phase 3)Looking for participantsNCT07207070
What this trial is testing

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Risen (Suzhou) Pharma Tech Co., Ltd. 312
Testing effectiveness (Phase 2)Looking for participantsNCT06029270
What this trial is testing

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Who this might be right for
Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharyngeal CarcinomaStage IV Nasopharyngeal Carcinoma AJCC v8
National Cancer Institute (NCI) 156
Not applicableActive Not RecruitingNCT07092254
What this trial is testing

Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Daiichi Sankyo 760
Testing effectiveness (Phase 2)Study completedNCT02312622
What this trial is testing

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Who this might be right for
Stage IV Non-small Cell Lung Cancer (NSCLC)Recurrent Non-small Cell Lung Cancer (NSCLC)Extensive-stage Small Cell Lung Cancer (SCLC)+3 more
Joel Neal 27
Testing effectiveness (Phase 2)Study completedNCT00005961
What this trial is testing

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

Who this might be right for
Melanoma (Skin)
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Study completedNCT00003670
What this trial is testing

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Eli Lilly and Company
Not applicableEnded earlyNCT02149173
What this trial is testing

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Who this might be right for
Estrogen Receptor PositiveRecurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7
University of Washington 29
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07005583
What this trial is testing

Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer (TNBC)
Tianjin Medical University Cancer Institute and Hospital 46
Testing effectiveness (Phase 2)Ended earlyNCT00319683
What this trial is testing

ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Adherex Technologies, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT00496756
What this trial is testing

Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer

Who this might be right for
Kidney Cancer
University of Nebraska 14
Early research (Phase 1)Study completedNCT00033241
What this trial is testing

Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors

Who this might be right for
Pancreatic CancerUnspecified Adult Solid Tumor, Protocol Specific
OSI Pharmaceuticals
Early research (Phase 1)Study completedNCT02916095
What this trial is testing

Kanitinib in Treating Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumors
Beijing Konruns Pharmaceutical Co., Ltd. 9
Testing effectiveness (Phase 2)Looking for participantsNCT07022002
What this trial is testing

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

Who this might be right for
Locally Advanced, Recurrent or Metastatic Malignancies
Shenyang Sunshine Pharmaceutical Co., LTD. 340
Early research (Phase 1)Study completedNCT02437370
What this trial is testing

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

Who this might be right for
Metastatic Urothelial Carcinoma of the Renal Pelvis and UreterRecurrent Bladder CarcinomaRecurrent Urothelial Carcinoma of the Renal Pelvis and Ureter+6 more
University of California, Davis 32
Testing effectiveness (Phase 2)Study completedNCT04623775
What this trial is testing

Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung CancerRecurrent Non-small Cell Lung CancerMetastatic Non-small Cell Lung Cancer
Bristol-Myers Squibb 468
Testing effectiveness (Phase 2)Study completedNCT00004865
What this trial is testing

Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy

Who this might be right for
Head and Neck Cancer
Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00217607
What this trial is testing

Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery

Who this might be right for
Sarcoma
UNICANCER 30
Next Page